Cellumed improves financial structure with 17 billion won capital increase... Change in largest shareholder and sharp drop in debt ratio
Completed a third-party allotment capital increase of 17 billion won, with TDI Landmark Union 1 becoming the new largest shareholder (replacing InscoBI)
Consolidated debt ratio plummeted from 625.94% to 186.87%; separate debt ratio improved from 215.54% to 86.64%
Consolidated net borrowings turned negative, from 5.46 billion won to -5.79 billion won (net cash position)
Consolidated Q1 revenue of 23.4 billion won, operating loss of 1.58 billion won, net loss of 1.71 billion won
Accumulated deficit of 144.8 billion won; capital impairment resolved but losses persist
Final settlement of Endotec royalty lawsuit for 17.6 billion won, with remaining payable of 11.0 billion won
Pursuing new businesses such as mRNA vaccine production enzymes; holds 54 patents
No shareholder return plans such as treasury stock cancellation or dividends